| HOME >> BIOLOGY >> TECHNOLOGY |
SAN DIEGO, April 7, 2008 /PRNewswire-FirstCall/ -- Ardea Biosciences,
Inc. (Nasdaq: RDEA) today announced that data will be presented on its
second generation non-nucleoside reverse transcriptase inhibitors (NNRTIs),
at the 21st International Conference on Antiviral Research (ICAR).
Additionally, data on two of the Company's mitogen-activated ERK kinase
(MEK) inhibitors, RDEA119 and RDEA436, will be presented at the American
Association for Cancer Research (AACR) annual meeting.
The presentation details are as follows:
-- 21st ICAR in Montreal, Quebec, Canada
Date/Time: Monday, April 14, 2008 at 4:00 p.m. Eastern Time
Title: A Novel NNRTI Class with Potent Anti-HIV Activity against
NNRTI-Resistant Viruses
Location: Poster Session 1 (Poster #80)
-- AACR Annual Meeting in San Diego, California
Date/Time: Tuesday, April 15, 2008 at 1:00 p.m. Pacific Time
Title: RDEA119, a Potent and Highly Specific MEK Inhibitor is
Efficacious in Mouse Tumor Xenograft Studies
Location: Poster Session 32 (Poster #4878), Exhibit Hall B-F
Date/Time: Tuesday, April 15, 2008 at 1:00 p.m. Pacific Time
Title: RDEA436, a Novel MEK Inhibitor with Favorable
Pharmacokinetic Properties
Location: Poster Session 32 (Poster #4895), Exhibit Hall B-F
About Ardea Biosciences, Inc.
Ardea Biosciences, of San Diego, California, is a biotechnology company
focused on the discovery and development of small-molecule therapeutics for
the treatment of HIV, cancer and inflammatory diseases, including gout. We
have three drug candidates in clinical trials and several others in
'/>"/>
| SOURCE Ardea Biosciences, Inc. Copyright©2008 PR Newswire. All rights reserved |